Literature DB >> 10515857

Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera.

A R Moliterno1, J L Spivak.   

Abstract

Recently, we demonstrated a marked reduction in the expression of the thrombopoietin receptor, Mpl, in polycythemia vera (PV) platelets and megakaryocytes using an antiserum against the Mpl extracellular domain. To further examine this abnormality, we raised an antibody to the Mpl C-terminus. Immunologic analysis of PV platelets with this antiserum confirmed the reduction in Mpl expression. However, the C-terminal antiserum detected 2 forms of Mpl in PV platelets in contrast to normal platelets, in which a single form of Mpl was detected by both the extracellular domain and C-terminal antisera. Two-dimensional gel electrophoresis studies with isoelectric focusing in the first dimension identified normal platelet Mpl as an 85 to 92 kD protein with an isoelectric point (pI) of 5.5. PV platelets contained an additional 80 to 82 kD Mpl Mpl isoform with a pI of 6.5. Analysis of Mpl expressed by the human megakaryocytic cell line, Dami, showed 2 isoforms similar to those found in PV platelets suggesting a precursor-product relationship. Digestion of Dami cell and normal platelet lysates with neuraminidase converted the more acidic Mpl isoform to the more basic one, indicating that the 2 isoforms differed with respect to posttranslational glycosylation. Furthermore, in contrast to normal platelet Mpl, PV platelet Mpl was susceptible to endoglycosidase H digestion, indicating defective Mpl processing by PV megakaryocytes. The glycosylation defect was specific for Mpl, as 2 other platelet membrane glycoproteins, glycoprotein IIb and multimerin, were processed normally. Importantly, the extent of the PV platelet Mpl glycosylation defect correlated with disease duration and extramedullary hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10515857

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Basic sciences of the myeloproliferative diseases: pathogenic mechanisms of ET and PV.

Authors:  Rosemary E Gale
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.

Authors:  Alison R Moliterno; Donna M Williams; Ophelia Rogers; Jerry L Spivak
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

3.  JAK2 V617F and the evolving paradigm of polycythemia vera.

Authors:  Robert T Means
Journal:  Korean J Hematol       Date:  2010-06-30

Review 4.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 5.  Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

6.  Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells.

Authors:  Min Lu; Lijuan Xia; Yen-Chun Liu; Tsivia Hochman; Laetizia Bizzari; Daniel Aruch; Jane Lew; Rona Weinberg; Judith D Goldberg; Ronald Hoffman
Journal:  Blood       Date:  2015-05-28       Impact factor: 22.113

7.  Mpl traffics to the cell surface through conventional and unconventional routes.

Authors:  Cédric Cleyrat; Anza Darehshouri; Mara P Steinkamp; Mathias Vilaine; Daniela Boassa; Mark H Ellisman; Sylvie Hermouet; Bridget S Wilson
Journal:  Traffic       Date:  2014-07-18       Impact factor: 6.215

8.  Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis.

Authors:  Alison R Moliterno; Donna M Williams; Laura I Gutierrez-Alamillo; Roberto Salvatori; Roxann G Ingersoll; Jerry L Spivak
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-21       Impact factor: 11.205

9.  Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity.

Authors:  Caroline Marty; Ronan Chaligné; Catherine Lacout; Stefan N Constantinescu; William Vainchenker; Jean-Luc Villeval
Journal:  J Biol Chem       Date:  2009-03-04       Impact factor: 5.157

10.  YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation.

Authors:  Ian S Hitchcock; Maximus M Chen; Jennifer R King; Kenneth Kaushansky
Journal:  Blood       Date:  2008-05-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.